ScholarIQanswers from OpenAlex & ORCID
Axel Grothey
ResearcherPublications, citations & collaboration network
Axel Grothey is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Axel Grothey have?
ScholarIQindexed works
Axel Grothey has 583 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Axel Grothey have?
ScholarIQcitation count
Axel Grothey has 37,998 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Axel Grothey?
ScholarIQh-index
Axel Grothey has an h-index of 77 in OpenAlex.
What is the i10-index of Axel Grothey?
ScholarIQi10-index
Axel Grothey has an i10-index of 238 in OpenAlex.
What is the ORCID of Axel Grothey?
ScholarIQorcid
The ORCID for Axel Grothey is on the source record.
What is the OpenAlex record for Axel Grothey?
ScholarIQopenalex
The OpenAlex for Axel Grothey is on the source record.
What are the most-cited papers on Axel Grothey?
ScholarIQmost cited works
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
Scott Kopetz, George J. Chang, Michael J. Overman, Cathy Eng, Daniel J. Sargent, David W. Larson, Axel Grothey, Jean‐Nicolas Vauthey, David M. Nagorney, Robert R. McWilliams
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto Sobrero, Anthony F. Shields, Takayuki Yoshino, James Paul, Julien Taı̈eb, John Souglakos, Qian Shi, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Déwi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Jeffrey P. Meyers, Lindsay A. Renfro, Donna Niedzwiecki, Toshiaki Watanabe, Valter Torri, Mark Saunders, Daniel J. Sargent, Thierry André, Timothy Iveson
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
Yucai Wang, Shouhao Zhou, Fang Yang, Xinyue Qi, Xin Wang, Xiaoxiang Guan, Chan Shen, Narjust Duma, Jesus Vera Aguilera, Ashish V. Chintakuntlawar, Katharine A. Price, Julian R. Molina, Lance C. Pagliaro, Þorvarður R. Hálfdánarson, Axel Grothey, Svetomir N. Markovic, Grzegorz S. Nowakowski, Stephen M. Ansell, Michael Wang